Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.75 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1241942 | 0.91 | NR1I2 (0.68) | NR1I2MAOBJAK1RORC | |
| SCHEMBL1243513 | 0.90 | NR1I2 (0.77) | NR1I2KDM4AKDM5AKDM4CKDM5B | |
| SCHEMBL1243520 | 0.89 | NR1I2 (0.75) | NR1I2 | |
| SCHEMBL1244229 | 0.89 | NR1I2 (0.71) | NR1I2 | |
| SCHEMBL1244392 | 0.89 | NR1I2 (0.71) | NR1I2 | |
| SCHEMBL1244612 | 0.87 | NR1I2 (0.55) | NR1I2MAOB | |
| SCHEMBL1242149 | 0.86 | NR1I2 (1.00) | NR1I2 | |
| SCHEMBL1244657 | 0.85 | NR1I2 (0.68) | NR1I2JAK1 | |
| SCHEMBL1242104 | 0.84 | NR1I2 (0.82) | NR1I2 | |
| SCHEMBL1243524 | 0.83 | NR1I2 (0.69) | NR1I2KDM4AKDM5AKDM4CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915373-B1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-1915373-B1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20110183959-A1 | P38 KINASE INHIBITING AGENTS | CHEN MENG-HSIN | 2011-07-28 | — | — | US | disclosed |
| US-20110183959-A1 | P38 KINASE INHIBITING AGENTS | CHEN MENG-HSIN | 2011-07-28 | — | — | US | disclosed |
| US-20110183959-A1 | P38 KINASE INHIBITING AGENTS | CHEN MENG-HSIN | 2011-07-28 | — | — | US | disclosed |
| US-7879875-B2 | such as 6-(2,4-difluorophenyl)-1-[2-fluoro-5-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-2H-quinolizin-2-one, used as antipyretics, analgesics, or in the treatment of arthritis, osteoarthritis, eczema, psoriasis and vision defects | Merk Sharp & Dohme Corp. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7879875-B2 | such as 6-(2,4-difluorophenyl)-1-[2-fluoro-5-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-2H-quinolizin-2-one, used as antipyretics, analgesics, or in the treatment of arthritis, osteoarthritis, eczema, psoriasis and vision defects | Merk Sharp & Dohme Corp. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7879875-B2 | such as 6-(2,4-difluorophenyl)-1-[2-fluoro-5-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-2H-quinolizin-2-one, used as antipyretics, analgesics, or in the treatment of arthritis, osteoarthritis, eczema, psoriasis and vision defects | Merk Sharp & Dohme Corp. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090131472-A1 | P38 Kinase Inhibiting Agents | MERCK SHARP & DOHME LLC | 2009-05-21 | — | — | US | disclosed |
| US-20090131472-A1 | P38 Kinase Inhibiting Agents | MERCK SHARP & DOHME LLC | 2009-05-21 | — | — | US | disclosed |
| US-20090131472-A1 | P38 Kinase Inhibiting Agents | MERCK SHARP & DOHME LLC | 2009-05-21 | — | — | US | disclosed |
| EP-1915373-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | Merck and Co., Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007021710-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007021710-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131472-A1 | P38 Kinase Inhibiting Agents | MAPK1, MAPK8, MAPK7 | NR1I2 417/4885MAOB 779/4885JAK1 98/4885 |
| US-20110183959-A1 | P38 KINASE INHIBITING AGENTS | MAPK1, MAPK8, MAPK7 | NR1I2 589/4885MAOB 634/4885JAK1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.